Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Blinatumomab Boosts EFS in Children With High-Risk B-ALL (opens in a new tab)

medscape.com · 2026-09-25

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly supported

Every claim we could check holds up. Three of four claims match the study. This overall rating is based only on the claims we could check. One claim the study doesn't address.

  • 3 supported
  • 1 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4Not coveredThe article says 4-year overall survival did not differ significantly between groups, and relapse was less frequent with blinatumomab.View evidenceHide evidence

As statedoverall survival 93.6% vs 91.0%; relapse 11.8% vs 21.4%

Why this verdict

The supplied abstract-level profile does not report 4-year overall survival results or relapse rates, so the stated overall-survival and relapse figures cannot be verified from the provided evidence depth. The profile does define relapse as part of the event-free survival endpoint, but it does not provide the separate relapse frequency or overall-survival comparison cited by the story.

1

Study evidence

Replacement of two post-consolidation chemotherapy cycles with two cycles of blinatumomab improved estimated 4-year event-free survival in the intention-to-treat analysis.HR 0.51 (95% CI, 0.35 to 0.73); estimated 4-year EFS 83.0% (95% CI, 77.4–87.4) vs 70.3% (95% CI, 63.8–75.9); P = 0.0002

“We randomly assigned, in a 1:1 ratio, children with high-risk B-cell ALL to receive two cycles of blinatumomab ... or two cycles of chemotherapy (control group) after consolidation.”
Claim 2 of 4SupportedA phase 3 trial found that replacing two cycles of intensive chemotherapy with two cycles of blinatumomab significantly improved event-free survival among children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia.View evidenceHide evidence

As statedsignificantly improved

Why this verdict

The abstract-level profile supports the central headline claim: in a randomized trial of children with newly diagnosed high-risk B-cell ALL, replacing two post-consolidation chemotherapy cycles with two cycles of blinatumomab significantly improved event-free survival versus chemotherapy control, with estimated HR 0.51 and P=0.0002. Because this was an interventional randomized comparison, the story’s causal framing is not overstated at this depth. The supplied profile supports a randomized trial but does not separately emphasize the 'phase 3' label.

1

Study evidence

Replacement of two post-consolidation chemotherapy cycles with two cycles of blinatumomab improved estimated 4-year event-free survival in the intention-to-treat analysis.HR 0.51 (95% CI, 0.35 to 0.73); estimated 4-year EFS 83.0% (95% CI, 77.4–87.4) vs 70.3% (95% CI, 63.8–75.9); P = 0.0002

“We randomly assigned, in a 1:1 ratio, children with high-risk B-cell ALL to receive two cycles of blinatumomab ... or two cycles of chemotherapy (control group) after consolidation.”
Claim 3 of 4SupportedThe article says the estimated 4-year event-free survival rates were 83.0% with blinatumomab and 70.3% with continued chemotherapy.View evidenceHide evidence

As stated83.0% vs 70.3%

Why this verdict

The reported estimated 4-year event-free survival rates match the abstract profile: 83.0% in the blinatumomab group versus 70.3% in the control chemotherapy group, with corresponding confidence intervals and significant intention-to-treat result.

1

Study evidence

Replacement of two post-consolidation chemotherapy cycles with two cycles of blinatumomab improved estimated 4-year event-free survival in the intention-to-treat analysis.HR 0.51 (95% CI, 0.35 to 0.73); estimated 4-year EFS 83.0% (95% CI, 77.4–87.4) vs 70.3% (95% CI, 63.8–75.9); P = 0.0002

“We randomly assigned, in a 1:1 ratio, children with high-risk B-cell ALL to receive two cycles of blinatumomab ... or two cycles of chemotherapy (control group) after consolidation.”
Claim 4 of 4SupportedBlinatumomab was also associated with fewer treatment-related infections and life-threatening adverse events, but neurotoxic events were more frequent.View evidenceHide evidence

As statedtreatment-related infections 23.9% vs 69.4%; life-threatening adverse events 0.5% vs 4.7%; neurotoxic events 12.0% vs 3.2%

Why this verdict

The safety comparisons are supported by the abstract profile: treatment-related infections were 23.9% with blinatumomab versus 69.4% with control chemotherapy, life-threatening adverse events were 0.5% versus 4.7%, and neurotoxic events were more frequent with blinatumomab, 12.0% versus 3.2%.

1

Study evidence

Treatment‑related infections were less frequent in the blinatumomab group (23.9%) than in the chemotherapy control group (69.4%) (P<0.001).23.9% vs 69.4%; P<0.001

“Infection related to the trial treatment occurred in 23.9% of patients in the blinatumomab group and in 69.4% of those in the control group (P<0.001).”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The efficacy result comes from a planned interim analysis at median follow-up of 2.9 years; longer follow-up is needed to confirm durability of the 4-year EFS estimates.

    This is a material limitation in the abstract profile. The story presentation mentions that overall survival was not significantly different at reported follow-up, but its listed caveats do not acknowledge that the EFS estimates themselves came from a planned interim analysis with median follow-up shorter than 4 years and that durability remains to be confirmed.

    From Randomized controlled trial (parallel-group, 1:1)

  • Cytokine release syndrome of grade 2 or higher occurred in 1.1% of patients in the blinatumomab group.

    The abstract profile includes cytokine release syndrome as a secondary safety finding, but the story presentation does not mention it.

    From Randomized controlled trial (safety outcomes reported)

3 things the story did carry across
  • Randomized interventional comparison in children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia after consolidation, assigning patients to two cycles of blinatumomab versus two cycles of chemotherapy.
  • Primary endpoint result: event-free survival was significantly higher with blinatumomab replacement, with estimated 4-year EFS 83.0% versus 70.3%, HR 0.51, and P=0.0002 in an intention-to-treat analysis.
  • Safety profile: blinatumomab replacement was associated with fewer treatment-related infections and fewer life-threatening adverse events but more neurotoxic events.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoDetermine whether replacing two post-consolidation chemotherapy cycles with two cycles of blinatumomab improves event-free survival in children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (ALL).Randomized controlled trial (parallel-group, 1:1)Expand

In plain English

In the AIEOP-BFM ALL 2017 randomized trial, replacing two post-consolidation chemotherapy cycles with two cycles of blinatumomab in children with newly diagnosed high-risk B‑cell ALL was associated with higher estimated 4-year event-free survival and a different safety profile at a planned interim analysis.

Key findings

  • Replacement of two post-consolidation chemotherapy cycles with two cycles of blinatumomab improved estimated 4-year event-free survival in the intention-to-treat analysis.HR 0.51 (95% CI, 0.35 to 0.73); estimated 4-year EFS 83.0% (95% CI, 77.4–87.4) vs 70.3% (95% CI, 63.8–75.9); P = 0.0002
  • Treatment-related infections were less frequent in the blinatumomab group than in the chemotherapy control group.23.9% vs 69.4% (P < 0.001)
“We randomly assigned, in a 1:1 ratio, children with high-risk B-cell ALL to receive two cycles of blinatumomab ... or two cycles of chemotherapy (control group) after consolidation.”
What this piece can’t prove
  • Reported efficacy estimates for 4-year event-free survival are from a planned interim analysis with a median follow-up of 2.9 years; longer follow-up is needed to confirm durability.

1 further detail could not be confirmed from the summary.

2human in vivoCompare safety and tolerability between blinatumomab replacement and chemotherapy control, including infections, life-threatening adverse events, neurotoxicity, and cytokine release syndrome.Randomized controlled trial (safety outcomes reported)Expand

In plain English

Within this randomized trial of children with newly diagnosed high‑risk B‑cell ALL, reported safety comparisons show lower treatment-related infections and fewer life‑threatening adverse events with replacement of two chemotherapy cycles by blinatumomab, but higher rates of neurotoxic events with blinatumomab; cytokine release syndrome (grade ≥2) was infrequent (1.1%) in the blinatumomab group.

Key findings

  • Treatment‑related infections were less frequent in the blinatumomab group (23.9%) than in the chemotherapy control group (69.4%) (P<0.001).23.9% vs 69.4%; P<0.001
  • Life‑threatening adverse events occurred in 2 patients (0.5%) in the blinatumomab group (including one fatal event, 0.3%) versus 16 patients (4.7%) in the control group.0.5% (2 patients; 1 fatal, 0.3%) vs 4.7% (16 patients)
“Infection related to the trial treatment occurred in 23.9% of patients in the blinatumomab group and in 69.4% of those in the control group (P<0.001).”
What this piece can’t prove

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Candidate

Faculty Opinions recommendation of Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2021 · Crossref

Source (opens in a new tab)

And 10 more candidates considered.